// App-Quantinova.ai

8503 : Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Jonathan Spicer

Principal Investigators

  • Fumihiro Tanaka

  • Gene Brian Saylors

  • Ke-Neng Chen

  • Moishe Liberman

  • Everett E. Vokes

  • Nicolas Girard

  • Shun Lu

  • Mariano Provencio

  • Tetsuya Mitsudomi

  • Mark M. Awad

  • Enriqueta Felip

  • Patrick M. Forde

  • Scott Swanson

  • Julie R. Brahmer

  • Keith Kerr

  • Ccile Dorange

  • Junliang Cai

  • Stephen Broderick

Medical Centers

  • McGill University Health Centre, Montreal, QC, Canada

  • Canada.

  • Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Charleston Oncology, Charleston, SC

  • Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China

  • Centre Hospitalier de l'Université de Montréal, Montreal

  • The University of Chicago Medical Center, Chicago, IL

  • Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France

  • Shanghai Lung Cancer Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China

  • Hospital Universitario Puerta de Hierro, Madrid, Spain

  • Kinki University Faculty of Medicine, Osaka, Japan

  • Dana-Farber Cancer Institute, Boston, MA

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Johns Hopkins Kimmel Cancer Center, Baltimore, MD

  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • Canada

  • China

  • Japan

  • United States

  • France

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Epidermal growth factor receptor

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02998528

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved